A204840 Stock Overview
Provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GL Pharm Tech Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,011.00 |
| 52 Week High | ₩1,540.00 |
| 52 Week Low | ₩944.00 |
| Beta | 1.09 |
| 1 Month Change | -0.79% |
| 3 Month Change | -12.99% |
| 1 Year Change | -15.82% |
| 3 Year Change | -9.33% |
| 5 Year Change | -4.17% |
| Change since IPO | -85.33% |
Recent News & Updates
Recent updates
Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?
Jul 23
Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% Higher
Mar 01Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?
Mar 30The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding On
Dec 15Shareholder Returns
| A204840 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.9% | 4.8% | 2.2% |
| 1Y | -15.8% | 1.8% | -8.3% |
Return vs Industry: A204840 underperformed the KR Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: A204840 underperformed the KR Market which returned -8.3% over the past year.
Price Volatility
| A204840 volatility | |
|---|---|
| A204840 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A204840 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A204840's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 27 | Hun-Sik Wang | www.glpt.co.kr |
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas.
GL Pharm Tech Corp. Fundamentals Summary
| A204840 fundamental statistics | |
|---|---|
| Market cap | ₩77.71b |
| Earnings (TTM) | -₩3.42b |
| Revenue (TTM) | ₩24.90b |
3.1x
P/S Ratio-22.7x
P/E RatioIs A204840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A204840 income statement (TTM) | |
|---|---|
| Revenue | ₩24.90b |
| Cost of Revenue | ₩15.77b |
| Gross Profit | ₩9.13b |
| Other Expenses | ₩12.54b |
| Earnings | -₩3.42b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -44.46 |
| Gross Margin | 36.65% |
| Net Profit Margin | -13.73% |
| Debt/Equity Ratio | 73.9% |
How did A204840 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 08:08 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GL Pharm Tech Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dong Oh Lim | IBK Securities Co. Ltd. |